Thymosin Alpha-1: What 35 Countries of Clinical Use and a Lopsided PCAC Vote Mean for Research Access in 2026

Key takeaways

• Thymosin alpha-1 (Tα1) is a 28-amino-acid peptide approved as Zadaxin in more than 35 countries for chronic hepatitis B, hepatitis C adjunct therapy, and immune support in oncology.
• The US FDA has never granted marketing authorisation for any Tα1 indication. The FDA's Pharmacy Compounding Advisory Committee (PCAC) voted 4–17 against placing thymosin alpha-1 on the 503A Bulks List at its December 2024 meeting, citing insufficient evidence of compounded-use effectiveness.
• Tα1 was originally placed on the FDA's Category 2 restricted compounding list in 2023, but was removed from Category 2 on 22 April 2026 as part of a broader HHS-directed reclassification. Removal from Category 2 does not constitute authorisation to compound.
• No MHRA marketing authorisation for thymosin alpha-1 exists in the UK as of August 2026, and MHRA's Products Register carries no matching approved product entry.
• For research procurement purposes, Tα1 occupies a distinct position from most BSR-tracked peptides: its international clinical record is materially stronger than that of BPC-157 or MOTS-c, yet its US compounding pathway is currently more restricted than those peptides, which received a favourable (if narrow) PCAC recommendation in July 2026.

What thymosin alpha-1 is

Thymosin alpha-1 is a naturally occurring 28-amino-acid peptide derived from prothymosin alpha, a protein produced in the thymus. It was first isolated in the 1970s by Allan Goldstein and colleagues at the George Washington University School of Medicine, and the synthetic form has since accumulated one of the more substantial clinical dossiers in the peptide field.

The peptide acts primarily as an immunomodulator. Its principal studied mechanism involves upregulation of T-cell maturation and differentiation, augmentation of natural killer cell activity, and enhancement of dendritic cell function. Preclinical and clinical work has also examined effects on cytokine production — particularly interferon-gamma and interleukin-2 — suggesting that Tα1 may shift immune responses toward a Th1-dominated profile. This mechanistic profile is the basis for its clinical investigation in viral hepatitis (where T-cell exhaustion is a recognised pathology) and in oncology settings where immune suppression limits treatment response.

The commercial form, Zadaxin (SciClone Pharmaceuticals / Alpha-1 Biomedical), is a synthetic formulation of thymalfasin — the INN for thymosin alpha-1 acetate — administered by subcutaneous injection.

The clinical evidence base

Tα1's clinical record spans more than three decades and distinguishes it meaningfully from many other peptides currently under FDA review.

Hepatitis B and C. Multiple randomised controlled trials conducted primarily in Asian populations have examined Tα1 in combination with interferon-alpha or antiviral regimens. A 2020 systematic review and meta-analysis in Frontiers in Pharmacology examined pooled data and found that Tα1 in combination with antiviral therapy was associated with higher rates of virological response in chronic hepatitis B compared to antiviral therapy alone. The data underpinning Zadaxin's approvals in more than 35 countries for hepatitis B and hepatitis C represent a body of evidence that few compounded peptides can match.

Oncology. Tα1 has been evaluated as an adjunct to chemotherapy in several tumour types, with interest centred on its potential to maintain immune competence during cytotoxic treatment. Studies in non-small-cell lung cancer and hepatocellular carcinoma have been published, though the evidence base in this area is more heterogeneous and the mechanistic benefit harder to isolate given confounding from concurrent regimens.

COVID-19. A cluster of investigator-initiated trials during 2020–2022 examined Tα1 in severe COVID-19, on the basis of its T-cell augmenting profile. Results from a Chinese multi-centre trial suggested potential mortality benefit in severe cases, but the studies were predominantly open-label and conducted during a period of rapidly evolving standard of care, limiting generalisability.

Immune deficiency and vaccine response. Smaller studies have examined Tα1 in DiGeorge syndrome (for which FDA has granted orphan drug designation) and in augmenting responses to influenza vaccination in elderly and immunocompromised populations.

Despite this record, the FDA's own staff concluded at the December 2024 PCAC meeting that the evidence for compounded Tα1 in the specific US 503A context — where pharmacies prepare custom-dosed formulations for individual patients — lacked the clinical effectiveness data required. The committee voted 4–17 against both thymosin alpha-1 free base and thymosin alpha-1 acetate for 503A Bulks List inclusion, with the majority citing an absence of compelling effectiveness data for the proposed compounded uses.

The 2026 regulatory position in the United States

Tα1's US regulatory history is procedurally unusual. The original 503A Bulks List nomination for thymosin alpha-1 was withdrawn by the nominator before the December 2024 PCAC meeting; however, the FDA elected to proceed with the review regardless. The result — a 4–17 vote against inclusion — is a non-binding committee recommendation, not a final FDA rule. The FDA retains authority to reach a different conclusion in any subsequent rulemaking.

In September 2023, Tα1 was placed on the FDA's Category 2 restricted bulk drug substances list, which effectively discouraged its use in compounding. On 22 April 2026, the FDA removed thymosin alpha-1 from Category 2 as part of a broader administrative action affecting approximately 12 peptides, following the direction of HHS Secretary Robert F. Kennedy Jr. However, practitioners and procurement professionals should note precisely what this removal did — and did not — accomplish.

As PeptideClarity's regulatory tracker documents, removal from Category 2 does not move a substance to Category 1, does not authorise 503A compounding, does not constitute enforcement discretion, and does not add the substance to the 503A Bulks List. A substance can only be lawfully compounded by a 503A pharmacy if it meets one of three statutory criteria: it has a USP or NF monograph, it is a component of an FDA-approved drug, or it appears on the 503A Bulks List. Thymosin alpha-1 meets none of these criteria in the United States as of October 2026.

No further PCAC review of thymosin alpha-1 has been announced. The second scheduled PCAC meeting — expected before the end of February 2027 — will address LL-37, Dihexa, GHK-Cu (injectable route), Melanotan II, and PEG-MGF, according to FDA announcements. Thymosin alpha-1 is not on that published agenda.

Separately, the FDA's April 2026 proposed rule to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List — announced by FDA Commissioner Marty Makary — illustrates the FDA's broader disposition toward restricting large-scale compounding of peptide-class agents where approved commercial alternatives exist. This posture is relevant context: Zadaxin has existing commercial manufacturing infrastructure, and the argument for clinical necessity in compounding is correspondingly harder to sustain.

UK and European regulatory position

No MHRA marketing authorisation for thymosin alpha-1 exists in the UK, as confirmed against the MHRA Products Register in August 2026. Zadaxin is not licensed as a medicinal product in Great Britain or Northern Ireland. The EMA has not granted a European marketing authorisation for any thymosin alpha-1 product.

For UK research procurement, this means Tα1 does not benefit from the regulatory scaffolding that surrounds a licensed medicine — no approved Summary of Product Characteristics, no licensed indication that could anchor a compounding or specials supply pathway, and no MHRA-approved quality standard. Procurement for legitimate research use requires sourcing from a reputable manufacturer with an appropriate Certificate of Analysis demonstrating identity, purity (typically ≥98% by HPLC), residual solvent testing, and endotoxin limits for injectable-grade material.

What distinguishes Tα1 from other BSR-tracked peptides

Tα1's position in the research landscape is genuinely distinctive. Unlike BPC-157 or MOTS-c, which received favourable PCAC votes in July 2026 despite having limited human clinical data, Tα1 carries an established international approval record as Zadaxin in over 35 countries and yet received one of the most decisive PCAC rejections in the 2024 review cycle — 4 votes in favour against 17 opposed.

The committee's reasoning is instructive: the PCAC was not assessing Tα1's overall scientific merit but evaluating whether sufficient evidence existed for its use in the specific context of US 503A compounding, at the doses and routes proposed by compounders. An approved drug in another jurisdiction does not automatically satisfy the FDA's evidentiary standard for bulk compounding, particularly where the approved form is commercially available and the proposed compounded forms diverge in dose or route. The committee majority found no compelling effectiveness data for Tα1 under those specific review parameters.

For researchers evaluating Tα1 as a subject of preclinical or translational study, the compound presents a richer clinical literature than many peptides currently attracting attention. For those assessing its procurement and regulatory risk profile, the current US and UK positions require careful attention: it is neither a licensed medicine in these jurisdictions nor currently on a pathway to compounding approval in the United States.

Sources

• FDA PCAC December 4, 2024 — Final Vote Summary (FDA.gov)
• FDA PCAC Briefing Document December 2024 — Thymosin Alpha-1 (FDA.gov)
• FDA proposes to exclude semaglutide, tirzepatide and liraglutide from 503B Bulks List (FDA.gov)
• GoodRx — Peptide FDA Updates: Latest News on Compounding and More (GoodRx.com)
• PeptideClarity Regulatory Tracker (getpeptideclarity.com)
• Thymosin Alpha-1 (Tα1): Approvals, Evidence & Legal Status 2026 (peptideclinicfinder.com)
• Superpower — Thymosin Peptides Guide (superpower.com)
• PCAC Peptide Review 2026: What the July Advisory Panel Decision Means (meto.co)
• Peptides Becoming Legal in 2026: The PCAC July 23–24 Meeting Explained (nootroholic.com)